Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Dementia01:30

Dementia

687
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
687
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Agile nudge implementation to improve minority recruitment in community-based research.

Frontiers in health services·2026
Same author

Optimizing scalable approaches for early detection of cognitive impairment in primary care.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Early prediction of postoperative delirium in major surgery patients using multimodal preoperative EHR and medical notes: a retrospective cohort study in the Indiana network for patient care.

BMJ public health·2026
Same author

Protocol for assessing urban-rural environmental stress disparities in ADRD through ecological momentary assessment (AURESIA).

Alzheimer's & dementia. Behavior & socioeconomics of aging·2026
Same author

Telehealth among Medicare Advantage beneficiaries with and without Alzheimer's Disease and Related Dementias (ADRD), 2018-2024: from pandemic-era surge to post-pandemic decline.

BMC health services research·2026
Same author

The Cirrhosis Medical Home: A Pilot Randomized Trial of a Collaborative Care Model for Patients With Decompensated Cirrhosis.

Clinical and translational gastroenterology·2026

関連する実験動画

Updated: May 1, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

36.6K

この患者さんは認知症ですか?

Tracey Holsinger1, Janie Deveau, Malaz Boustani

  • 1Department of Psychiatry, Durham VA Medical Center, Durham, NC, USA. tracey.holsinger@va.gov

JAMA
|June 7, 2007
PubMed
まとめ

短期的な認知スクリーニングテストは,初等医療における認知症の診断に役立ちます. The Memory Impairment Screenとインフォマントレポートは,高齢者の認知障害を検出する有望なことを示しています.

科学分野:

  • ゲロントロジーはゲロントロジーの学科です.
  • 神経学 神経学とは
  • プライマリーケア医療 プライマリーケア医療

背景:

  • 米国では何百万人もの人々が認知症や記憶障害を経験しています.
  • 認知障害の早期発見は,認知症の早期診断に不可欠です.
  • 簡潔なスクリーニングツールは,初等保健施設で役立ちます.

研究 の 目的:

  • プライマリケアにおける簡潔な認知スクリーニングの実用性と正確性に関する文献をレビューする.
  • 認知症の認知スクリーニングツールに関する以前のレビューを更新する.

主な方法:

  • MEDLINEとpsychINFOのデータベース (2000-2006年) で検索しました.
  • 認知症の診断が確認された60歳以上の患者の研究も含まれています.
  • 25の異なるスクリーニングツールを使用して,適格性および品質のための29の研究を評価しました.

主要な成果:

  • 38のユニークな楽器/研究組み合わせを評価しました.
  • ミニメンタルステート試験 (MMSE) は,6.3 (陽性) と0.19 (陰性) の中位確率比 (LRs) を示した.
  • メモリー障害スクリーン (4分) はLRsが33 (陽性) と0.08 (陰性) であった. 情報提供者の報告では,認知症のLRは6.5であった.

さらに関連する動画

Oral Health Assessment by Lay Personnel for Older Adults
08:47

Oral Health Assessment by Lay Personnel for Older Adults

Published on: February 2, 2020

12.4K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.1K

関連する実験動画

Last Updated: May 1, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

36.6K
Oral Health Assessment by Lay Personnel for Older Adults
08:47

Oral Health Assessment by Lay Personnel for Older Adults

Published on: February 2, 2020

12.4K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.1K

結論:

  • 臨床医は,患者集団と人口統計スコア効果の認識に基づいて,プライマリスクリーニングツールを選択する必要があります.
  • 特定の状況のための二次ツールを追加することを検討してください.
  • 時計描画テストは有用ですが,適切なスコア付けを必要とし,軽度の障害を見逃す可能性があります.